Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
about
Activation of regulatory T cells during inflammatory response is not an exclusive property of stem cellsInterleukin-7 ameliorates immune dysfunction and improves survival in a 2-hit model of fungal sepsis.Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy.Altered Toll-like receptor 2-mediated endotoxin tolerance is related to diminished interferon beta production.
P2860
Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
@en
Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
@nl
type
label
Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
@en
Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
@nl
prefLabel
Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
@en
Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
@nl
P2860
P356
P1476
Immunomodulatory cell therapy in sepsis: have we learnt lessons from the past?
@en
P2093
Guillaume Monneret
P2860
P304
P356
10.1586/ERI.10.107
P577
2010-10-01T00:00:00Z